5月14日 - ** 癌症药物制造商ExelixisEXEL.O股价盘前上涨5.6%至39美元
** 该公司在周二晚些时候（(link)）将2025年的营收预期上调至22.5亿至23.5亿美元，之前的预期为21.5亿至22.5亿美元。
** 公司公布的第一季度总收益为 5.554 亿美元，高于分析师预计的 4.982 亿美元--数据由 LSEG 编制
** 公司公布的第一季度副利润为每股 62 美分，高于预期的每股 36 美分，主要得益于其抗癌药物 Cabometyx 的销售。
** 截至上次收盘，股价累计上涨 11
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.